Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, The Lancet Respiratory Medicine

In patients ≥40 with Covid-19 and ≥1 high-risk characteristic (n=4488), colchicine (0.5mg twice daily for 3 days, then once daily for 27 days) was not associated with a statistically significant reduction in death or Covid-19 hospital admission (4.7% v 5.8% placebo; p=0.081).
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news